Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), sold 6,845 shares at $1.08 ($7K) on 2026-05-20, disclosed to the SEC on 2026-05-22.
Scheduled sale ($7k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |